Quality of Life in @entity902 -Sensitive Recurrent XXXX : Chemotherapy Versus Surgery Plus Chemotherapy.

@entity1 @entity43 @entity4886 @entity158 @entity1142 @entity902
PURPOSE: This study was designed to compare quality of life in a sample of Italian @entity1 affected by @entity902 -sensitive recurrent @entity43 and submitted to chemotherapy alone or secondary cytoreductive surgery plus chemotherapy through validated questionnaires. METHODS: From January 2007 to December 2012, consecutive @entity1 with suspicious recurrence of @entity43 , referred to the Division of Gynecologic Oncology at the University Campus Bio-Medico of Rome, were assessed for this prospective, case-control study. After a diagnostic laparoscopy, surgical resectable @entity1 were enrolled in group A (surgery plus chemotherapy). @entity1 not suitable for optimal debulking surgery and all @entity1 who refused surgery were enrolled in group B (chemotherapy alone). At beginning of treatment, after the third and sixth cycle of chemotherapy, all eligible @entity1 were asked to fill in QLQ-C30 (version 3.0) and EORTC QLQ-OV28 questionnaires. RESULTS: Group A included 38 @entity1 and underwent @entity4886 followed by chemotherapy; group B included 16 @entity1 that were submitted to chemotherapy alone. Quality-of-life scores of both questionnaires were comparable between groups, with the exception of @entity1142 and @entity158 , which resulted significantly worsened in Group A at 3  months. This difference was no longer present at 6  months. Median overall survival was 72  % for Group A and 56  % in Group B at median follow-up of 35  months for Group A and 32  months for Group B. CONCLUSIONS: Both surgery followed by chemotherapy and chemotherapy alone seem to have a negligible impact on QOL. @entity4886 plus chemotherapy seems to be an effective and tolerable therapeutic option in @entity902 -sensitive recurrences.
